Lee Newman
Concepts (553)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Occupational Health | 34 | 2025 | 208 | 14.330 |
Why?
| | Occupational Exposure | 35 | 2025 | 348 | 7.480 |
Why?
| | Farmers | 15 | 2025 | 70 | 7.290 |
Why?
| | Small Business | 14 | 2022 | 51 | 7.210 |
Why?
| | Saccharum | 16 | 2025 | 77 | 7.050 |
Why?
| | Heat Stress Disorders | 12 | 2025 | 82 | 5.440 |
Why?
| | Berylliosis | 37 | 2018 | 193 | 5.430 |
Why?
| | Hot Temperature | 13 | 2025 | 403 | 4.840 |
Why?
| | Beryllium | 31 | 2018 | 161 | 4.560 |
Why?
| | Renal Insufficiency, Chronic | 15 | 2025 | 623 | 4.160 |
Why?
| | Workplace | 26 | 2024 | 269 | 3.580 |
Why?
| | Occupational Injuries | 7 | 2023 | 44 | 3.570 |
Why?
| | Agricultural Workers' Diseases | 6 | 2025 | 31 | 3.470 |
Why?
| | Occupational Diseases | 11 | 2025 | 162 | 3.280 |
Why?
| | Guatemala | 19 | 2025 | 347 | 2.640 |
Why?
| | Health Promotion | 12 | 2024 | 757 | 2.580 |
Why?
| | Agriculture | 7 | 2024 | 99 | 2.320 |
Why?
| | Leadership | 7 | 2025 | 396 | 2.070 |
Why?
| | Workers' Compensation | 4 | 2019 | 27 | 1.820 |
Why?
| | Organizational Culture | 6 | 2024 | 162 | 1.690 |
Why?
| | Kidney | 10 | 2025 | 1482 | 1.490 |
Why?
| | Sarcoidosis | 13 | 2012 | 161 | 1.380 |
Why?
| | Safety Management | 6 | 2021 | 126 | 1.320 |
Why?
| | Creatinine | 7 | 2025 | 489 | 1.320 |
Why?
| | Humans | 149 | 2025 | 141197 | 1.310 |
Why?
| | Adult | 68 | 2025 | 39181 | 1.300 |
Why?
| | Glomerular Filtration Rate | 5 | 2021 | 750 | 1.300 |
Why?
| | Chronic Disease | 28 | 2025 | 1816 | 1.160 |
Why?
| | Occupational Medicine | 2 | 2025 | 13 | 1.150 |
Why?
| | Longitudinal Studies | 13 | 2025 | 2902 | 1.110 |
Why?
| | Population Surveillance | 4 | 2025 | 481 | 1.100 |
Why?
| | Dehydration | 5 | 2025 | 54 | 1.100 |
Why?
| | Male | 82 | 2025 | 69789 | 1.090 |
Why?
| | Middle Aged | 63 | 2025 | 34438 | 1.080 |
Why?
| | Body Temperature | 2 | 2025 | 224 | 1.070 |
Why?
| | Absenteeism | 2 | 2018 | 52 | 1.060 |
Why?
| | Heat-Shock Response | 2 | 2025 | 77 | 1.010 |
Why?
| | Health Behavior | 5 | 2022 | 790 | 1.000 |
Why?
| | Lymphocytes | 4 | 2018 | 398 | 0.990 |
Why?
| | Biomarkers | 8 | 2024 | 4175 | 0.990 |
Why?
| | HSP70 Heat-Shock Proteins | 3 | 2024 | 74 | 0.920 |
Why?
| | Efficiency | 3 | 2024 | 100 | 0.890 |
Why?
| | Inservice Training | 1 | 2025 | 122 | 0.870 |
Why?
| | Colorado | 19 | 2023 | 4610 | 0.870 |
Why?
| | Industry | 4 | 2019 | 68 | 0.870 |
Why?
| | Body Temperature Regulation | 1 | 2025 | 100 | 0.850 |
Why?
| | Inhalation Exposure | 2 | 2025 | 108 | 0.840 |
Why?
| | Air Pollution | 2 | 2025 | 322 | 0.800 |
Why?
| | Environmental Monitoring | 6 | 2025 | 371 | 0.790 |
Why?
| | Developing Countries | 1 | 2025 | 317 | 0.770 |
Why?
| | Point-of-Care Testing | 2 | 2023 | 35 | 0.770 |
Why?
| | Occupational Stress | 1 | 2023 | 42 | 0.770 |
Why?
| | Female | 68 | 2025 | 75522 | 0.750 |
Why?
| | Air Pollutants | 4 | 2020 | 430 | 0.720 |
Why?
| | Acute Kidney Injury | 2 | 2019 | 819 | 0.680 |
Why?
| | Neurophysins | 1 | 2020 | 5 | 0.650 |
Why?
| | Arsenic | 1 | 2021 | 63 | 0.650 |
Why?
| | Risk Factors | 24 | 2025 | 10438 | 0.640 |
Why?
| | Tobacco Smoke Pollution | 2 | 2021 | 256 | 0.640 |
Why?
| | Anemia | 1 | 2021 | 177 | 0.640 |
Why?
| | Mexico | 3 | 2025 | 232 | 0.640 |
Why?
| | Capacity Building | 1 | 2020 | 62 | 0.640 |
Why?
| | Glycopeptides | 1 | 2020 | 43 | 0.630 |
Why?
| | Analgesics, Opioid | 2 | 2018 | 1116 | 0.630 |
Why?
| | Vasopressins | 1 | 2020 | 60 | 0.630 |
Why?
| | HLA-DP Antigens | 6 | 2011 | 33 | 0.620 |
Why?
| | Respiratory Hypersensitivity | 4 | 2004 | 68 | 0.620 |
Why?
| | Protein Precursors | 1 | 2020 | 133 | 0.610 |
Why?
| | Cross-Sectional Studies | 12 | 2021 | 5636 | 0.600 |
Why?
| | Program Evaluation | 4 | 2025 | 928 | 0.600 |
Why?
| | Particulate Matter | 4 | 2025 | 330 | 0.590 |
Why?
| | Presenteeism | 1 | 2018 | 5 | 0.590 |
Why?
| | Latin America | 3 | 2025 | 91 | 0.580 |
Why?
| | Veterinarians | 1 | 2018 | 12 | 0.580 |
Why?
| | Young Adult | 14 | 2025 | 13673 | 0.570 |
Why?
| | Mass Screening | 4 | 2025 | 1310 | 0.570 |
Why?
| | Cell Proliferation | 5 | 2018 | 2504 | 0.570 |
Why?
| | Smoking | 8 | 2021 | 1601 | 0.560 |
Why?
| | Sleep | 2 | 2023 | 877 | 0.550 |
Why?
| | Drug Utilization | 1 | 2018 | 169 | 0.550 |
Why?
| | Accidents, Occupational | 2 | 2015 | 13 | 0.550 |
Why?
| | CD4-Positive T-Lymphocytes | 13 | 2011 | 1110 | 0.550 |
Why?
| | Body Composition | 1 | 2021 | 701 | 0.540 |
Why?
| | Text Messaging | 1 | 2020 | 179 | 0.530 |
Why?
| | Extraction and Processing Industry | 2 | 2014 | 9 | 0.530 |
Why?
| | Clinical Laboratory Techniques | 1 | 2018 | 96 | 0.530 |
Why?
| | Mental Health | 1 | 2024 | 749 | 0.530 |
Why?
| | Work Performance | 1 | 2017 | 6 | 0.530 |
Why?
| | Health Personnel | 1 | 2024 | 737 | 0.520 |
Why?
| | Metabolic Diseases | 1 | 2018 | 114 | 0.520 |
Why?
| | Professional Role | 1 | 2018 | 168 | 0.520 |
Why?
| | Guidelines as Topic | 1 | 2018 | 273 | 0.500 |
Why?
| | Lymphocyte Activation | 17 | 2014 | 1150 | 0.500 |
Why?
| | Renal Insufficiency | 1 | 2018 | 169 | 0.490 |
Why?
| | Federal Government | 1 | 2016 | 27 | 0.490 |
Why?
| | Environmental Exposure | 8 | 2013 | 582 | 0.480 |
Why?
| | Health Policy | 1 | 2019 | 403 | 0.480 |
Why?
| | Sarcoidosis, Pulmonary | 8 | 2010 | 87 | 0.470 |
Why?
| | Food Industry | 1 | 2015 | 16 | 0.460 |
Why?
| | Hypertension | 2 | 2025 | 1252 | 0.460 |
Why?
| | CpG Islands | 1 | 2015 | 163 | 0.460 |
Why?
| | Antigens, Bacterial | 4 | 2012 | 125 | 0.460 |
Why?
| | United States | 17 | 2025 | 15220 | 0.450 |
Why?
| | Safety | 2 | 2015 | 356 | 0.450 |
Why?
| | Tumor Necrosis Factor-alpha | 5 | 2015 | 1250 | 0.450 |
Why?
| | Prevalence | 4 | 2025 | 2772 | 0.440 |
Why?
| | Climate Change | 4 | 2025 | 187 | 0.440 |
Why?
| | Occupational Health Services | 1 | 2014 | 35 | 0.430 |
Why?
| | Guideline Adherence | 1 | 2018 | 565 | 0.430 |
Why?
| | Chronic Pain | 1 | 2018 | 280 | 0.430 |
Why?
| | Oil and Gas Fields | 1 | 2014 | 32 | 0.420 |
Why?
| | Pulmonary Fibrosis | 3 | 2005 | 400 | 0.410 |
Why?
| | Natural Gas | 4 | 2014 | 25 | 0.400 |
Why?
| | Granuloma, Respiratory Tract | 4 | 2007 | 12 | 0.400 |
Why?
| | Lung | 12 | 2019 | 4134 | 0.390 |
Why?
| | Life Style | 1 | 2015 | 482 | 0.370 |
Why?
| | Risk Reduction Behavior | 1 | 2014 | 227 | 0.370 |
Why?
| | Mycobacterium | 3 | 2009 | 112 | 0.360 |
Why?
| | Influenza, Human | 2 | 2022 | 626 | 0.350 |
Why?
| | Air Pollutants, Occupational | 4 | 2025 | 41 | 0.350 |
Why?
| | Cost-Benefit Analysis | 1 | 2014 | 618 | 0.340 |
Why?
| | Promoter Regions, Genetic | 1 | 2015 | 1242 | 0.340 |
Why?
| | Aged | 23 | 2021 | 24576 | 0.340 |
Why?
| | Mass Spectrometry | 1 | 2014 | 739 | 0.340 |
Why?
| | DNA Methylation | 1 | 2015 | 645 | 0.330 |
Why?
| | Mycobacterium Infections | 2 | 2012 | 62 | 0.330 |
Why?
| | Logistic Models | 7 | 2022 | 2086 | 0.330 |
Why?
| | Opioid-Related Disorders | 1 | 2018 | 562 | 0.320 |
Why?
| | Ferritins | 2 | 2014 | 67 | 0.320 |
Why?
| | HLA-DP beta-Chains | 7 | 2014 | 91 | 0.320 |
Why?
| | Macrophages, Alveolar | 2 | 2004 | 396 | 0.320 |
Why?
| | Employment | 2 | 2024 | 181 | 0.320 |
Why?
| | Electrolytes | 2 | 2020 | 56 | 0.320 |
Why?
| | Air Pollution, Indoor | 3 | 2019 | 184 | 0.310 |
Why?
| | Practice Patterns, Physicians' | 1 | 2018 | 1336 | 0.310 |
Why?
| | Mental Disorders | 1 | 2018 | 1120 | 0.310 |
Why?
| | Macrophages | 2 | 2015 | 1560 | 0.310 |
Why?
| | Health Status | 3 | 2021 | 823 | 0.300 |
Why?
| | B-Lymphocytes | 1 | 2014 | 858 | 0.290 |
Why?
| | Temperature | 2 | 2023 | 669 | 0.290 |
Why?
| | Data Collection | 1 | 2011 | 661 | 0.290 |
Why?
| | HLA Antigens | 4 | 2010 | 233 | 0.290 |
Why?
| | Multivariate Analysis | 6 | 2018 | 1490 | 0.290 |
Why?
| | Perception | 3 | 2021 | 376 | 0.290 |
Why?
| | Delivery of Health Care | 1 | 2016 | 961 | 0.290 |
Why?
| | Sensitivity and Specificity | 8 | 2023 | 1973 | 0.290 |
Why?
| | HLA-DR Antigens | 7 | 2010 | 228 | 0.280 |
Why?
| | Insurance Claim Reporting | 2 | 2018 | 27 | 0.270 |
Why?
| | T-Lymphocytes | 3 | 2014 | 2003 | 0.270 |
Why?
| | Time Factors | 5 | 2025 | 6956 | 0.270 |
Why?
| | Immunization | 3 | 2005 | 406 | 0.270 |
Why?
| | Program Development | 2 | 2020 | 368 | 0.260 |
Why?
| | Genetic Predisposition to Disease | 8 | 2010 | 2363 | 0.260 |
Why?
| | Police | 1 | 2007 | 45 | 0.260 |
Why?
| | Respiratory Protective Devices | 2 | 2007 | 15 | 0.260 |
Why?
| | Methamphetamine | 1 | 2007 | 67 | 0.260 |
Why?
| | Cancer Survivors | 2 | 2024 | 297 | 0.260 |
Why?
| | Internet | 1 | 2011 | 690 | 0.260 |
Why?
| | Wyoming | 2 | 2018 | 27 | 0.260 |
Why?
| | Apoptosis | 4 | 2005 | 2574 | 0.250 |
Why?
| | Case-Control Studies | 10 | 2018 | 3588 | 0.250 |
Why?
| | Spectrometry, Mass, Secondary Ion | 1 | 2005 | 2 | 0.240 |
Why?
| | Central Nervous System Stimulants | 1 | 2007 | 178 | 0.240 |
Why?
| | Prospective Studies | 5 | 2020 | 7739 | 0.240 |
Why?
| | Plutonium | 1 | 2005 | 4 | 0.240 |
Why?
| | Incidence | 3 | 2025 | 2794 | 0.240 |
Why?
| | Neopterin | 2 | 2003 | 13 | 0.240 |
Why?
| | Chemical Industry | 1 | 2005 | 11 | 0.230 |
Why?
| | Bronchoalveolar Lavage Fluid | 9 | 2009 | 650 | 0.230 |
Why?
| | Organism Hydration Status | 1 | 2025 | 9 | 0.230 |
Why?
| | Cohort Studies | 6 | 2019 | 5799 | 0.230 |
Why?
| | alpha 1-Antitrypsin Deficiency | 1 | 2006 | 62 | 0.230 |
Why?
| | Pilot Projects | 2 | 2021 | 1820 | 0.230 |
Why?
| | Antigen Presentation | 4 | 2014 | 220 | 0.230 |
Why?
| | Research | 3 | 2018 | 455 | 0.220 |
Why?
| | Proteomics | 2 | 2011 | 1135 | 0.220 |
Why?
| | Nuclear Warfare | 1 | 2004 | 10 | 0.220 |
Why?
| | Kidney Diseases | 2 | 2019 | 406 | 0.220 |
Why?
| | Humidity | 1 | 2024 | 50 | 0.220 |
Why?
| | Pandemics | 3 | 2022 | 1654 | 0.210 |
Why?
| | Cadmium | 2 | 2022 | 68 | 0.210 |
Why?
| | Diabetes Mellitus | 2 | 2025 | 1074 | 0.210 |
Why?
| | Age of Onset | 1 | 2006 | 532 | 0.210 |
Why?
| | Prognosis | 6 | 2020 | 4073 | 0.210 |
Why?
| | Research Design | 2 | 2022 | 1143 | 0.210 |
Why?
| | Electronic Health Records | 1 | 2011 | 1122 | 0.200 |
Why?
| | Risk Assessment | 5 | 2021 | 3490 | 0.200 |
Why?
| | Pneumoconiosis | 2 | 2004 | 20 | 0.200 |
Why?
| | Volcanic Eruptions | 1 | 2022 | 5 | 0.190 |
Why?
| | Residence Characteristics | 2 | 2018 | 368 | 0.190 |
Why?
| | Inflammation Mediators | 3 | 2014 | 519 | 0.190 |
Why?
| | Vaccination | 1 | 2011 | 1467 | 0.190 |
Why?
| | Ventilation | 2 | 2019 | 44 | 0.190 |
Why?
| | Receptors, Fibroblast Growth Factor | 1 | 2002 | 68 | 0.190 |
Why?
| | Antibodies | 1 | 2024 | 409 | 0.190 |
Why?
| | Lymphangioleiomyomatosis | 1 | 2002 | 36 | 0.190 |
Why?
| | Nephrology | 1 | 2023 | 61 | 0.190 |
Why?
| | Immunity, Active | 1 | 2002 | 11 | 0.190 |
Why?
| | Metals, Heavy | 1 | 2022 | 31 | 0.190 |
Why?
| | Crops, Agricultural | 2 | 2019 | 29 | 0.190 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2003 | 369 | 0.180 |
Why?
| | Respiratory Function Tests | 5 | 2019 | 567 | 0.180 |
Why?
| | Metals | 2 | 2004 | 140 | 0.180 |
Why?
| | Information Dissemination | 1 | 2024 | 224 | 0.180 |
Why?
| | Health Surveys | 2 | 2018 | 505 | 0.180 |
Why?
| | Medical Oncology | 1 | 2024 | 316 | 0.180 |
Why?
| | Models, Immunological | 1 | 2002 | 101 | 0.180 |
Why?
| | Calculi | 1 | 2021 | 16 | 0.180 |
Why?
| | Respiratory Tract Infections | 1 | 2006 | 385 | 0.180 |
Why?
| | Cotinine | 1 | 2021 | 77 | 0.180 |
Why?
| | Focus Groups | 1 | 2024 | 565 | 0.180 |
Why?
| | Organizational Innovation | 1 | 2022 | 138 | 0.180 |
Why?
| | Fibroblast Growth Factors | 1 | 2002 | 180 | 0.170 |
Why?
| | Nickel | 1 | 2021 | 62 | 0.170 |
Why?
| | Aged, 80 and over | 8 | 2011 | 7856 | 0.170 |
Why?
| | Beverages | 1 | 2020 | 67 | 0.160 |
Why?
| | Virus Diseases | 1 | 2022 | 215 | 0.160 |
Why?
| | Policy | 1 | 2021 | 149 | 0.160 |
Why?
| | Noise, Occupational | 1 | 2019 | 3 | 0.160 |
Why?
| | Transcription, Genetic | 1 | 2006 | 1487 | 0.160 |
Why?
| | HLA-DQ Antigens | 4 | 2010 | 178 | 0.160 |
Why?
| | Kidney Function Tests | 1 | 2020 | 157 | 0.160 |
Why?
| | Sri Lanka | 1 | 2019 | 7 | 0.150 |
Why?
| | Specific Gravity | 1 | 2019 | 11 | 0.150 |
Why?
| | Central America | 1 | 2019 | 24 | 0.150 |
Why?
| | Hemoglobins | 1 | 2021 | 361 | 0.150 |
Why?
| | Neoplasms | 4 | 2024 | 2741 | 0.150 |
Why?
| | Blood Proteins | 2 | 2011 | 250 | 0.150 |
Why?
| | Social Support | 1 | 2023 | 633 | 0.150 |
Why?
| | Climate | 1 | 2019 | 89 | 0.150 |
Why?
| | India | 1 | 2019 | 208 | 0.150 |
Why?
| | Nutritional Status | 1 | 2021 | 362 | 0.150 |
Why?
| | Unemployment | 1 | 2018 | 43 | 0.150 |
Why?
| | Work Capacity Evaluation | 1 | 2018 | 11 | 0.140 |
Why?
| | Global Health | 2 | 2016 | 386 | 0.140 |
Why?
| | Interferon-gamma | 5 | 2015 | 792 | 0.140 |
Why?
| | Headache Disorders | 1 | 2018 | 19 | 0.140 |
Why?
| | Digestive System Diseases | 1 | 2018 | 26 | 0.140 |
Why?
| | False Positive Reactions | 1 | 2018 | 125 | 0.140 |
Why?
| | Urologic Diseases | 1 | 2018 | 39 | 0.140 |
Why?
| | Asbestosis | 2 | 2011 | 13 | 0.140 |
Why?
| | Granuloma | 2 | 2014 | 97 | 0.140 |
Why?
| | Cytokines | 4 | 2014 | 2098 | 0.140 |
Why?
| | Models, Psychological | 1 | 2020 | 313 | 0.140 |
Why?
| | Survivorship | 1 | 2018 | 50 | 0.140 |
Why?
| | Allopurinol | 1 | 2018 | 62 | 0.140 |
Why?
| | Musculoskeletal Pain | 1 | 2018 | 39 | 0.140 |
Why?
| | Educational Status | 1 | 2020 | 463 | 0.140 |
Why?
| | Reference Standards | 1 | 2018 | 186 | 0.140 |
Why?
| | Adolescent | 7 | 2021 | 22007 | 0.140 |
Why?
| | Benchmarking | 1 | 2019 | 188 | 0.140 |
Why?
| | Catalase | 2 | 2009 | 134 | 0.140 |
Why?
| | Body Mass Index | 2 | 2018 | 2382 | 0.140 |
Why?
| | Fever | 1 | 2019 | 308 | 0.140 |
Why?
| | Physical Exertion | 1 | 2019 | 209 | 0.140 |
Why?
| | Lung Diseases, Interstitial | 1 | 2004 | 655 | 0.140 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2006 | 1049 | 0.140 |
Why?
| | Adaptation, Physiological | 1 | 2022 | 560 | 0.140 |
Why?
| | Job Satisfaction | 1 | 2020 | 221 | 0.140 |
Why?
| | Awareness | 1 | 2018 | 103 | 0.130 |
Why?
| | Arthritis | 1 | 2018 | 104 | 0.130 |
Why?
| | Epidemics | 1 | 2018 | 92 | 0.130 |
Why?
| | Self Report | 1 | 2021 | 856 | 0.130 |
Why?
| | Hyperthermia, Induced | 1 | 2018 | 120 | 0.130 |
Why?
| | Antibodies, Monoclonal | 3 | 2012 | 1448 | 0.130 |
Why?
| | Respiratory Tract Diseases | 1 | 2018 | 181 | 0.130 |
Why?
| | Drug Prescriptions | 1 | 2018 | 262 | 0.130 |
Why?
| | Nuclear Energy | 1 | 2016 | 2 | 0.120 |
Why?
| | Nuclear Power Plants | 1 | 2016 | 3 | 0.120 |
Why?
| | Community Health Planning | 1 | 2016 | 43 | 0.120 |
Why?
| | Diagnosis, Differential | 4 | 2004 | 1498 | 0.120 |
Why?
| | Public-Private Sector Partnerships | 1 | 2016 | 45 | 0.120 |
Why?
| | HLA-DRB1 Chains | 6 | 2010 | 112 | 0.120 |
Why?
| | Proportional Hazards Models | 1 | 2019 | 1261 | 0.120 |
Why?
| | Hypersensitivity | 2 | 2012 | 257 | 0.120 |
Why?
| | Fibroblast Growth Factor 2 | 1 | 1996 | 87 | 0.120 |
Why?
| | Immunity, Innate | 1 | 2002 | 852 | 0.120 |
Why?
| | Linear Models | 1 | 2018 | 857 | 0.120 |
Why?
| | Cell Line, Transformed | 2 | 2014 | 145 | 0.120 |
Why?
| | Population Health | 1 | 2016 | 48 | 0.120 |
Why?
| | Mice | 8 | 2019 | 18055 | 0.120 |
Why?
| | Cell Line | 2 | 2015 | 2885 | 0.120 |
Why?
| | Motivation | 1 | 2020 | 602 | 0.110 |
Why?
| | Medical Laboratory Personnel | 2 | 2006 | 6 | 0.110 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2024 | 1396 | 0.110 |
Why?
| | Heart Diseases | 1 | 2018 | 335 | 0.110 |
Why?
| | Recurrence | 1 | 2018 | 1110 | 0.110 |
Why?
| | Radiography, Thoracic | 4 | 2006 | 178 | 0.110 |
Why?
| | Liver Diseases | 1 | 2018 | 301 | 0.110 |
Why?
| | Mast Cells | 1 | 1996 | 149 | 0.110 |
Why?
| | Macrophage Activation | 1 | 2015 | 200 | 0.110 |
Why?
| | Enzyme Inhibitors | 1 | 2018 | 854 | 0.110 |
Why?
| | Ions | 1 | 2014 | 67 | 0.110 |
Why?
| | Community Health Services | 1 | 2016 | 233 | 0.110 |
Why?
| | Fruit | 1 | 2015 | 147 | 0.110 |
Why?
| | Disease Progression | 5 | 2011 | 2793 | 0.110 |
Why?
| | Communication | 1 | 2020 | 945 | 0.110 |
Why?
| | Research Personnel | 1 | 2016 | 183 | 0.100 |
Why?
| | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2 | 2011 | 145 | 0.100 |
Why?
| | Endotoxins | 2 | 2006 | 220 | 0.100 |
Why?
| | Vegetables | 1 | 2015 | 161 | 0.100 |
Why?
| | Allergens | 3 | 2006 | 401 | 0.100 |
Why?
| | Immunologic Memory | 3 | 2005 | 360 | 0.100 |
Why?
| | Community-Based Participatory Research | 2 | 2025 | 164 | 0.100 |
Why?
| | Health Impact Assessment | 1 | 2013 | 9 | 0.100 |
Why?
| | Retrospective Studies | 4 | 2020 | 16273 | 0.100 |
Why?
| | Models, Biological | 1 | 2021 | 1828 | 0.100 |
Why?
| | Genotype | 6 | 2011 | 1859 | 0.100 |
Why?
| | Water Supply | 2 | 2016 | 86 | 0.090 |
Why?
| | Sex Factors | 1 | 2018 | 2059 | 0.090 |
Why?
| | Cell Division | 2 | 2004 | 798 | 0.090 |
Why?
| | Maximum Allowable Concentration | 2 | 2019 | 16 | 0.090 |
Why?
| | Hydrocarbons | 1 | 2012 | 30 | 0.090 |
Why?
| | Antigens, Fungal | 1 | 2012 | 27 | 0.090 |
Why?
| | Up-Regulation | 2 | 2006 | 859 | 0.090 |
Why?
| | Paper | 1 | 2011 | 10 | 0.090 |
Why?
| | Personnel, Hospital | 1 | 2011 | 32 | 0.090 |
Why?
| | Bacterial Proteins | 2 | 2009 | 911 | 0.090 |
Why?
| | T-Lymphocyte Subsets | 2 | 2005 | 415 | 0.090 |
Why?
| | Health Services Research | 1 | 2014 | 406 | 0.090 |
Why?
| | Vital Capacity | 2 | 2019 | 312 | 0.090 |
Why?
| | Pulmonary Gas Exchange | 2 | 2004 | 124 | 0.090 |
Why?
| | Liver | 2 | 2018 | 1819 | 0.090 |
Why?
| | Forced Expiratory Volume | 2 | 2019 | 489 | 0.080 |
Why?
| | Glutamic Acid | 2 | 2003 | 256 | 0.080 |
Why?
| | Schools, Veterinary | 1 | 2010 | 2 | 0.080 |
Why?
| | Alleles | 4 | 2011 | 891 | 0.080 |
Why?
| | Practice Guidelines as Topic | 1 | 2018 | 1597 | 0.080 |
Why?
| | Gene Expression Regulation | 2 | 2019 | 2599 | 0.080 |
Why?
| | Genes, MHC Class II | 1 | 2010 | 75 | 0.080 |
Why?
| | Mesalamine | 1 | 2009 | 10 | 0.080 |
Why?
| | Sulfasalazine | 1 | 2009 | 23 | 0.080 |
Why?
| | Phenotype | 3 | 2010 | 3166 | 0.080 |
Why?
| | Animals | 10 | 2019 | 37663 | 0.080 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2012 | 348 | 0.080 |
Why?
| | Cell Separation | 2 | 2009 | 317 | 0.080 |
Why?
| | Substance-Related Disorders | 1 | 2018 | 1100 | 0.080 |
Why?
| | Uveitis | 1 | 2010 | 148 | 0.070 |
Why?
| | Silicosis | 1 | 1989 | 29 | 0.070 |
Why?
| | Latent Tuberculosis | 1 | 2009 | 68 | 0.070 |
Why?
| | Swimming Pools | 1 | 2007 | 6 | 0.070 |
Why?
| | Hydrotherapy | 1 | 2007 | 7 | 0.070 |
Why?
| | Alcohol Drinking | 1 | 2015 | 834 | 0.070 |
Why?
| | Receptors, Antigen, T-Cell | 2 | 2004 | 720 | 0.070 |
Why?
| | Crime | 1 | 2007 | 60 | 0.070 |
Why?
| | Animal Technicians | 2 | 2006 | 3 | 0.070 |
Why?
| | RNA, Messenger | 2 | 2006 | 2828 | 0.070 |
Why?
| | Water Microbiology | 1 | 2007 | 88 | 0.070 |
Why?
| | Severity of Illness Index | 4 | 2007 | 2892 | 0.070 |
Why?
| | Spirometry | 3 | 2019 | 264 | 0.070 |
Why?
| | Tomography, X-Ray Computed | 1 | 1997 | 2746 | 0.060 |
Why?
| | Aerosols | 1 | 2007 | 181 | 0.060 |
Why?
| | Cells, Cultured | 5 | 2009 | 4208 | 0.060 |
Why?
| | Influenza Vaccines | 1 | 2011 | 551 | 0.060 |
Why?
| | Biopsy | 3 | 2005 | 1081 | 0.060 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2007 | 171 | 0.060 |
Why?
| | Genetic Markers | 2 | 2010 | 343 | 0.060 |
Why?
| | Transcription Factor AP-1 | 1 | 2006 | 88 | 0.060 |
Why?
| | Gene Dosage | 1 | 2006 | 141 | 0.060 |
Why?
| | Reactive Oxygen Species | 2 | 2008 | 630 | 0.060 |
Why?
| | Polymorphism, Genetic | 2 | 2010 | 627 | 0.060 |
Why?
| | Risk | 2 | 2007 | 904 | 0.060 |
Why?
| | RNA Precursors | 1 | 2006 | 156 | 0.060 |
Why?
| | Biopsy, Needle | 2 | 2002 | 187 | 0.060 |
Why?
| | Chromosomes, Human, X | 1 | 2005 | 77 | 0.060 |
Why?
| | Leukocytes, Mononuclear | 2 | 2006 | 573 | 0.060 |
Why?
| | Radioisotopes | 1 | 2004 | 35 | 0.050 |
Why?
| | Genetic Linkage | 1 | 2005 | 288 | 0.050 |
Why?
| | Immunosuppressive Agents | 1 | 2009 | 854 | 0.050 |
Why?
| | Psychological Tests | 1 | 2005 | 136 | 0.050 |
Why?
| | HLA-DRB3 Chains | 1 | 2003 | 2 | 0.050 |
Why?
| | HLA-DRB5 Chains | 1 | 2003 | 2 | 0.050 |
Why?
| | fas Receptor | 1 | 2004 | 97 | 0.050 |
Why?
| | HLA-DRB4 Chains | 1 | 2003 | 6 | 0.050 |
Why?
| | Antioxidants | 1 | 2008 | 595 | 0.050 |
Why?
| | Odds Ratio | 3 | 2014 | 1052 | 0.050 |
Why?
| | Radiation Dosage | 1 | 2005 | 191 | 0.050 |
Why?
| | HLA-DQ beta-Chains | 1 | 2003 | 62 | 0.050 |
Why?
| | Biomarkers, Tumor | 1 | 2011 | 1252 | 0.050 |
Why?
| | Phagocytes | 1 | 2004 | 103 | 0.050 |
Why?
| | CD28 Antigens | 1 | 2003 | 58 | 0.050 |
Why?
| | Tuberculosis | 1 | 2006 | 285 | 0.050 |
Why?
| | Chi-Square Distribution | 1 | 2004 | 521 | 0.050 |
Why?
| | Immunologic Tests | 1 | 2003 | 16 | 0.050 |
Why?
| | Animals, Laboratory | 1 | 2003 | 20 | 0.050 |
Why?
| | Treatment Outcome | 3 | 2014 | 11120 | 0.050 |
Why?
| | Public Health | 2 | 2022 | 587 | 0.050 |
Why?
| | Exercise | 1 | 2015 | 2103 | 0.050 |
Why?
| | Kinetics | 1 | 2006 | 1652 | 0.050 |
Why?
| | Physiological Phenomena | 1 | 2002 | 3 | 0.050 |
Why?
| | Lipopolysaccharides | 1 | 2006 | 889 | 0.050 |
Why?
| | Culture Techniques | 1 | 2002 | 74 | 0.050 |
Why?
| | Contraindications | 1 | 2002 | 85 | 0.050 |
Why?
| | NF-kappa B | 1 | 2006 | 692 | 0.050 |
Why?
| | Disposable Equipment | 1 | 2002 | 21 | 0.050 |
Why?
| | Radiography | 2 | 2003 | 844 | 0.050 |
Why?
| | In Situ Nick-End Labeling | 1 | 2002 | 126 | 0.050 |
Why?
| | Genetic Variation | 1 | 2007 | 1000 | 0.050 |
Why?
| | Patch Tests | 1 | 2002 | 57 | 0.050 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2002 | 91 | 0.050 |
Why?
| | Epitopes | 1 | 2003 | 477 | 0.040 |
Why?
| | Statistics, Nonparametric | 1 | 2002 | 434 | 0.040 |
Why?
| | Nuclear Proteins | 1 | 2006 | 712 | 0.040 |
Why?
| | Nuclear Weapons | 2 | 2011 | 7 | 0.040 |
Why?
| | Oxygen Consumption | 1 | 2004 | 715 | 0.040 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2003 | 855 | 0.040 |
Why?
| | Reference Values | 1 | 2002 | 805 | 0.040 |
Why?
| | Equipment Design | 1 | 2002 | 525 | 0.040 |
Why?
| | Point-of-Care Systems | 1 | 2023 | 185 | 0.040 |
Why?
| | Exercise Test | 1 | 2003 | 625 | 0.040 |
Why?
| | ROC Curve | 2 | 2003 | 586 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2004 | 2064 | 0.040 |
Why?
| | Hearing Loss, Noise-Induced | 1 | 2019 | 13 | 0.040 |
Why?
| | 2,4-Dinitrophenol | 1 | 2019 | 9 | 0.040 |
Why?
| | Kidney Medulla | 1 | 2019 | 31 | 0.040 |
Why?
| | Infliximab | 2 | 2012 | 111 | 0.040 |
Why?
| | Amino Acid Sequence | 4 | 2009 | 2158 | 0.040 |
Why?
| | Patient Care Team | 1 | 2024 | 664 | 0.040 |
Why?
| | Molecular Sequence Data | 4 | 2009 | 2929 | 0.040 |
Why?
| | Acute Disease | 1 | 2002 | 1008 | 0.040 |
Why?
| | Selection Bias | 1 | 2018 | 41 | 0.040 |
Why?
| | Organizational Case Studies | 1 | 2018 | 78 | 0.040 |
Why?
| | Health | 1 | 2018 | 84 | 0.040 |
Why?
| | Transcription Factors | 1 | 2006 | 1703 | 0.040 |
Why?
| | Cities | 1 | 2018 | 134 | 0.040 |
Why?
| | Immunohistochemistry | 1 | 2002 | 1737 | 0.040 |
Why?
| | Quality of Life | 2 | 2012 | 2999 | 0.030 |
Why?
| | Xanthine Oxidase | 1 | 2018 | 81 | 0.030 |
Why?
| | Genetic Association Studies | 2 | 2010 | 372 | 0.030 |
Why?
| | Polymerase Chain Reaction | 2 | 2011 | 1056 | 0.030 |
Why?
| | Lung Neoplasms | 1 | 2011 | 2560 | 0.030 |
Why?
| | Haplotypes | 2 | 2010 | 496 | 0.030 |
Why?
| | Fibrosis | 1 | 2000 | 541 | 0.030 |
Why?
| | Uric Acid | 1 | 2018 | 165 | 0.030 |
Why?
| | Congresses as Topic | 1 | 2018 | 230 | 0.030 |
Why?
| | Histocompatibility Testing | 2 | 2009 | 123 | 0.030 |
Why?
| | Cost of Illness | 1 | 2018 | 312 | 0.030 |
Why?
| | Observer Variation | 1 | 1997 | 355 | 0.030 |
Why?
| | Administration, Oral | 1 | 2018 | 803 | 0.030 |
Why?
| | Gene Frequency | 2 | 2010 | 494 | 0.030 |
Why?
| | Community Health Nursing | 1 | 2016 | 63 | 0.030 |
Why?
| | Sanitation | 1 | 2016 | 55 | 0.030 |
Why?
| | Antibody Formation | 1 | 1997 | 298 | 0.030 |
Why?
| | Follow-Up Studies | 2 | 2021 | 5200 | 0.030 |
Why?
| | Poverty | 1 | 2019 | 530 | 0.030 |
Why?
| | Collagen | 1 | 2018 | 459 | 0.030 |
Why?
| | Dyspnea | 3 | 2005 | 257 | 0.030 |
Why?
| | Antigens | 1 | 1997 | 362 | 0.030 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 3 | 2002 | 335 | 0.030 |
Why?
| | Siblings | 2 | 2006 | 216 | 0.030 |
Why?
| | Double-Blind Method | 2 | 2012 | 1983 | 0.030 |
Why?
| | Community Participation | 1 | 2016 | 138 | 0.030 |
Why?
| | Education, Nursing | 1 | 2016 | 94 | 0.030 |
Why?
| | Asthma | 2 | 2019 | 1913 | 0.030 |
Why?
| | Disease Susceptibility | 2 | 2000 | 352 | 0.030 |
Why?
| | Universities | 1 | 2016 | 452 | 0.030 |
Why?
| | Neural Tube Defects | 1 | 2014 | 64 | 0.020 |
Why?
| | Cleft Palate | 1 | 2014 | 75 | 0.020 |
Why?
| | Infant, Low Birth Weight | 1 | 2014 | 146 | 0.020 |
Why?
| | Education, Medical | 1 | 2016 | 270 | 0.020 |
Why?
| | Interleukin-2 | 2 | 2005 | 453 | 0.020 |
Why?
| | Mitochondria | 1 | 2019 | 967 | 0.020 |
Why?
| | Bronchiolitis | 1 | 1993 | 85 | 0.020 |
Why?
| | Lung Diseases | 1 | 1999 | 794 | 0.020 |
Why?
| | Politics | 1 | 2013 | 102 | 0.020 |
Why?
| | Maternal Exposure | 1 | 2014 | 202 | 0.020 |
Why?
| | Epidemiological Monitoring | 1 | 2012 | 65 | 0.020 |
Why?
| | Enzyme-Linked Immunospot Assay | 1 | 2011 | 37 | 0.020 |
Why?
| | Pneumonia | 1 | 1997 | 656 | 0.020 |
Why?
| | Genes, T-Cell Receptor beta | 2 | 2002 | 23 | 0.020 |
Why?
| | Pregnancy | 2 | 2014 | 7070 | 0.020 |
Why?
| | Qualitative Research | 1 | 2018 | 1516 | 0.020 |
Why?
| | Finland | 1 | 2011 | 80 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 2011 | 386 | 0.020 |
Why?
| | Immunity, Cellular | 1 | 2012 | 269 | 0.020 |
Why?
| | Inflammation | 1 | 2002 | 2889 | 0.020 |
Why?
| | Netherlands | 1 | 2010 | 87 | 0.020 |
Why?
| | Hazardous Substances | 1 | 2010 | 17 | 0.020 |
Why?
| | Japan | 1 | 2010 | 133 | 0.020 |
Why?
| | Toxoplasma | 1 | 2010 | 45 | 0.020 |
Why?
| | Premature Birth | 1 | 2014 | 365 | 0.020 |
Why?
| | Salmonella enterica | 1 | 2010 | 57 | 0.020 |
Why?
| | United Kingdom | 1 | 2010 | 322 | 0.020 |
Why?
| | HLA-A Antigens | 1 | 1989 | 58 | 0.020 |
Why?
| | Antigen-Presenting Cells | 1 | 2009 | 159 | 0.020 |
Why?
| | HLA-B Antigens | 1 | 1989 | 64 | 0.020 |
Why?
| | Demography | 1 | 2009 | 296 | 0.020 |
Why?
| | Predictive Value of Tests | 2 | 2005 | 2070 | 0.020 |
Why?
| | Halogens | 1 | 2007 | 14 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2018 | 4405 | 0.020 |
Why?
| | Codon | 1 | 2007 | 92 | 0.020 |
Why?
| | Antineoplastic Agents | 1 | 2018 | 2166 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2018 | 5887 | 0.020 |
Why?
| | Tuberculin | 1 | 2006 | 8 | 0.020 |
Why?
| | Placebos | 1 | 2006 | 198 | 0.020 |
Why?
| | Cell Survival | 1 | 2009 | 1129 | 0.020 |
Why?
| | Disinfection | 1 | 2007 | 128 | 0.020 |
Why?
| | Host-Pathogen Interactions | 1 | 2009 | 372 | 0.020 |
Why?
| | Hydrogen Peroxide | 1 | 2007 | 339 | 0.020 |
Why?
| | Heart Defects, Congenital | 1 | 2014 | 875 | 0.010 |
Why?
| | Cluster Analysis | 1 | 2007 | 521 | 0.010 |
Why?
| | Eye | 1 | 2006 | 113 | 0.010 |
Why?
| | Decision Making | 1 | 2013 | 961 | 0.010 |
Why?
| | Caspase 8 | 1 | 2005 | 48 | 0.010 |
Why?
| | Flow Cytometry | 1 | 2009 | 1197 | 0.010 |
Why?
| | Genetic Techniques | 1 | 2005 | 67 | 0.010 |
Why?
| | Free Radical Scavengers | 1 | 2005 | 87 | 0.010 |
Why?
| | Lymphocyte Count | 1 | 2005 | 167 | 0.010 |
Why?
| | Ultraviolet Rays | 1 | 2007 | 401 | 0.010 |
Why?
| | Metalloporphyrins | 1 | 2005 | 105 | 0.010 |
Why?
| | Chromosome Mapping | 1 | 2005 | 504 | 0.010 |
Why?
| | Caspases | 1 | 2005 | 245 | 0.010 |
Why?
| | Species Specificity | 1 | 2005 | 583 | 0.010 |
Why?
| | Adenocarcinoma | 1 | 2011 | 892 | 0.010 |
Why?
| | Genome-Wide Association Study | 1 | 2010 | 1403 | 0.010 |
Why?
| | Abatacept | 1 | 2003 | 56 | 0.010 |
Why?
| | Radioallergosorbent Test | 1 | 2003 | 3 | 0.010 |
Why?
| | Dose-Response Relationship, Immunologic | 1 | 2003 | 85 | 0.010 |
Why?
| | Mycobacterium tuberculosis | 1 | 2006 | 320 | 0.010 |
Why?
| | Thymidine | 1 | 2003 | 60 | 0.010 |
Why?
| | Skin Tests | 1 | 2003 | 97 | 0.010 |
Why?
| | Geography | 1 | 2003 | 201 | 0.010 |
Why?
| | Genetic Testing | 1 | 2005 | 460 | 0.010 |
Why?
| | Statistics as Topic | 1 | 2003 | 302 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2014 | 6275 | 0.010 |
Why?
| | Th1 Cells | 1 | 2002 | 139 | 0.010 |
Why?
| | Immunoconjugates | 1 | 2003 | 126 | 0.010 |
Why?
| | Organ Specificity | 1 | 2002 | 312 | 0.010 |
Why?
| | Mice, Inbred A | 1 | 2001 | 51 | 0.010 |
Why?
| | Autoantibodies | 1 | 1989 | 1470 | 0.010 |
Why?
| | Ceramics | 1 | 2001 | 22 | 0.010 |
Why?
| | Mice, Inbred C3H | 1 | 2001 | 270 | 0.010 |
Why?
| | Oxidative Stress | 1 | 2008 | 1331 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 2002 | 1093 | 0.010 |
Why?
| | Sequence Alignment | 1 | 2001 | 363 | 0.010 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2001 | 391 | 0.010 |
Why?
| | Dogs | 1 | 2001 | 427 | 0.010 |
Why?
| | Genes, T-Cell Receptor alpha | 1 | 1999 | 12 | 0.010 |
Why?
| | Gene Rearrangement, alpha-Chain T-Cell Antigen Receptor | 1 | 1999 | 21 | 0.010 |
Why?
| | Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 1 | 1999 | 27 | 0.010 |
Why?
| | Forecasting | 1 | 2001 | 384 | 0.010 |
Why?
| | Models, Animal | 1 | 2001 | 396 | 0.010 |
Why?
| | Clone Cells | 1 | 1999 | 266 | 0.010 |
Why?
| | Models, Statistical | 1 | 2003 | 671 | 0.010 |
Why?
| | Cell Movement | 1 | 2002 | 990 | 0.010 |
Why?
| | Skin | 1 | 2002 | 765 | 0.010 |
Why?
| | Models, Molecular | 1 | 2001 | 1603 | 0.010 |
Why?
| | Depression | 1 | 2005 | 1483 | 0.010 |
Why?
| | Bronchography | 1 | 1993 | 11 | 0.010 |
Why?
| | Cough | 1 | 1993 | 129 | 0.010 |
Why?
| | Bronchoscopy | 1 | 1993 | 226 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2005 | 5929 | 0.010 |
Why?
| | Bronchiectasis | 1 | 1993 | 112 | 0.010 |
Why?
|
|
Newman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|